Elite Pharmaceuticals Appoints New Auditor

TL;DR

Elite Pharma switches auditors from EisnerAmper to Citrin Cooperman, no disagreements reported.

AI Summary

Elite Pharmaceuticals, Inc. announced on June 1, 2024, that it has appointed a new independent registered public accounting firm, Citrin Cooperman & Company, LLP, effective immediately. This change follows the resignation of their previous auditor, EisnerAmper LLP, on May 29, 2024. The company stated there were no disagreements with EisnerAmper LLP.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor.

Risk Assessment

Risk Level: low — This filing concerns a routine change of independent auditors, which typically carries low risk.

Key Players & Entities

• Elite Pharmaceuticals, Inc. (company) — Registrant
• Citrin Cooperman & Company, LLP (company) — New independent registered public accounting firm
• EisnerAmper LLP (company) — Former independent registered public accounting firm
• June 1, 2024 (date) — Effective date of auditor appointment
• May 29, 2024 (date) — Date of previous auditor's resignation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Indicate by

Filing Documents

• form8-k.htm (8-K) — 39KB
• ex16-1.htm (EX-16.1) — 4KB
• 0001493152-24-022732.txt ( ) — 211KB
• eltp-20240601.xsd (EX-101.SCH) — 3KB
• eltp-20240601_lab.xml (EX-101.LAB) — 33KB
• eltp-20240601_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

(a)(1)(v) of Regulation S-K and the related instructions thereto)

Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto). From the date of Mazars USA's appointment as the Company's registered public accounting firm` through June 1, 2024, there were (i) no "disagreements" within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto with Mazars USA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Mazars USA, would have caused it to make reference to the subject matter of the disagreements in connection with its reports on the consolidated financial statements of the Company for such periods, and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto. The Company provided Mazars USA with a copy of the disclosures under this Item 4.01 prior to the time this Current Report on Form 8-K was filed with the Securities and Exchange Commission, and the Company requested that Mazars USA furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made by the Company in this Item 4.01 and, if not, stating the respects in which it does not agree. A copy of Mazars USA's letter is filed as Exhibit 16.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Mazars USA letter dated June 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 5, 2024 ELITE PHARMACEUTICALS, INC. By: /s/ Carter J. Ward Carter J. Ward, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR